LenoMed is a company that develops and produces insulin pumps.
Sector: Life Sciences
Harlan Krumholz, MD
Harlan Krumholz joined F-Prime in August 2020 as a Venture Partner and is focused on transformative approaches to improve the delivery of care, conduct of research, and empowerment of people in their health decisions – and measures success by the positive, tangible effect on people’s lives. He believes in medicine as an information science and wants to advance approaches that make health care more effective, patient-centric, precise, convenient, equitable, efficient, and to position health care to be smarter with every interaction. He is the Harold H. Hines, Jr. Professor of Medicine at Yale University and the founding Director of the Yale New Haven Hospital Center for Outcomes Research and Evaluation, one of the nation’s first and most distinguished groups focusing on using applied science to improve health and healthcare. He is also a founder of two companies and an advisor for many others.
Harlan received his BS from Yale College, his MD from Harvard Medical School, and an SM from the Harvard School of Public Health.
RareStone
RareStone (formerly Citrine Medicine) is a rare disease-focused therapeutics company focused on the Greater China market that was co-founded by Eight Roads Ventures, F-Prime Capital and Vivo Capital. RareStone is dedicated to improving the lives of rare disease patients by making diagnosis and essential treatments available and accessible for those who need them.
Rallybio
Rallybio is a biopharmaceutical company focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Rallybio merged with Candid Therapeutics in 2026. The combined company will operate as Candid Therapeutics and trade on NASDAQ under the ticker CDRX.
Affinia Therapeutics
Affinia Therapeutics is a gene therapy company with a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies and a mission to develop transformative medicines for devastating diseases.
Amber Cai, PhD
Amber Cai is a Venture Partner with F-Prime, focusing on early-stage biotechnology investments. She is the founding CEO of Skyline Therapeutics, a leading gene and cell therapy company.
Prior to joining Skyline, Amber was a founding member of Novartis’ R&D Center in China, where she was most recently the Head of Operations and led the Center’s overall business operations overseeing a broad set of functions. During 2005-2006, Amber led the efforts to establish Novartis’ R&D presence in China from the concept stage to implementation. After the Center was established in 2006 as the first fully integrated research and development center in China by multinational pharma companies, she played an instrumental role in recruiting talent, establishing operations, developing Novartis’ China R&D strategy, and building strategic partnerships with government and other external stakeholders and collaborators. Prior to her work in China, Amber was with the Business Development at Novartis Institutes for BioMedical Researches in Cambridge, MA.
Amber has decades of experience in science before shifting her career into business. She completed her PhD at Massachusetts Institute of Technology in GPCR signaling and holds an MBA degree from MIT Sloan School of Management.
Muzammil Mansuri, PhD
Muz Mansuri joined F-Prime in January 2020 as a Venture Partner and is based in the Cambridge office. Muz will be working with various F-Prime team members to evaluate therapeutic and digital investment and company creation opportunities. Muz has more than 35 years of experience in various R&D roles as a senior executive within the global biopharmaceutical industry.
Prior to joining F-Prime, Muz was a member of the Executive Committee at Sanofi, as Executive Vice President, Strategy, Business Development, and Licensing. Among other responsibilities, Muz headed the Strategy, Business Development, Alliance Management and the Venture Group for Sanofi. Before this, he was at Gilead Sciences as Senior Vice President, Research and Development Strategy and Business Development. In that capacity he led the R&D Strategy, Business Development, and M&A activities for the company. Muz has served as Chief Executive Officer of several biotech companies and as a General Partner at Flagship Ventures (now Flagship Pioneering). He began his career in the pharmaceutical industry as a bench medicinal chemist with Bristol Myers.
Muz received his B.Sc. and PhD in Chemistry from the University College London. He conducted postdoctoral research at UCLA and Columbia University.
Nanos Medical
Nanos Medical develops, manufactures and markets minimally invasive interventional therapy medical devices in the field of ENT, cardiovascular and others.
Insilico Medicine
Insilico specializes in artificial intelligence for drug discovery, biomarker development and aging research.
Singular Genomics
Singular Genomics (NASDAQ: OMIC) is developing a new next generation sequencing platform.